2seventy bio announces Q1 2024 Abecma U.S. revenue of $52M

2seventy bio, Inc.

2024-Q1 EPS reported -$1.01 revenue$12,435,000

Abecma generated approximately $52M in U.S. Q1 2024 revenue, unaudited.
Company and BMS share equally in all profits and losses for Abecma in the U.S.
Full Q1 2024 results to be announced on or before May 15, 2024.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

2seventy bio, Inc. reported the first quarter of 2024 results: revenue $52 million.

Period: the first quarter of 2024
Revenue: $52 million
Result: preliminary results

Exact text from the filing

On April 25, 2024, 2seventy bio, Inc. (the “Company”) announced that Abecma (idecabtagene vicleucel, or ide-cel) generated approximately $52 million in U.S. revenue during the first quarter of 2024.

View on SEC.gov

485 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001860782-24-000060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.